Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 3:45 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 543064 | NSE: COHANCE

Cohance Lifesciences Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹407.30Undervalued by 30.54%vs CMP ₹312.00

P/E (39.7) × ROE (12.7%) × BV (₹99.00) × DY (2.00%)

₹167.55Overvalued by 46.30%vs CMP ₹312.00
MoS: -86.2% (Negative)Confidence: 58/100 (Moderate)Models: 1 Under, 1 Fair, 7 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹354.5422%Under (+13.6%)
Graham NumberEarnings₹140.8816%Over (-54.8%)
Earnings PowerEarnings₹56.3313%Over (-81.9%)
DCFCash Flow₹54.9913%Over (-82.4%)
Net Asset ValueAssets₹99.017%Over (-68.3%)
EV/EBITDAEnterprise₹130.019%Over (-58.3%)
Earnings YieldEarnings₹89.107%Over (-71.4%)
ROCE CapitalReturns₹311.259%Fair (-0.2%)
Revenue MultipleRevenue₹46.985%Over (-84.9%)
Consensus (9 models)₹167.55100%Overvalued
Key Drivers: Wide model spread (₹47–₹355) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: -13.0%

*Investments are subject to market risks

Investment Snapshot

55
Cohance Lifesciences Ltd scores 55/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health81/100 · Strong
ROCE 14.9% GoodROE 12.7% GoodD/E 0.11 Low debtInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money45/100 · Moderate
FII holding down -5.04% (6mo) SellingDII holding up 4.97% MF buyingPromoter holding at 57.5% Stable
Earnings Quality40/100 · Moderate
OPM contracting (44% → 35%) Declining
Quarterly Momentum50/100 · Moderate
Revenue (4Q): +23% YoY AcceleratingProfit (4Q): -38% YoY DecliningOPM: 18.0% (down 17.0% YoY) Margin pressure
Industry Rank40/100 · Moderate
P/E 39.7 vs industry 53.8 In-lineROCE 14.9% vs industry 16.4% Average3Y sales CAGR: -3% Shrinking

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Cohance Lifesciences Ltd Investor Signals

Computed from valuation, cash flow, balance sheet, ownership and quarterly trend data already available in this stock page.

Value Trap Score
70/100
High
Derived from: Cheapness + weak quality + weak cash support
Current data: P/E 39.7 vs Ind 53.8 | ROCE 14.9% | ROE 12.7% | CFO/NP N/A
Balance Sheet Stress
20/100
Comfortable
Derived from: Leverage + debt servicing + liquidity + debt trend
Current data: D/E 0.11x | IntCov 0.0x | Current 2.57x | Borrow/Reserve 0.12x
Cash Flow Reliability
43/100
Mixed
Derived from: Cash backing of earnings + working capital pressure
Current data: CFO ₹0 Cr | NP ₹265 Cr | CFO/NP N/A
Ownership Accumulation
0
Neutral
Derived from: FII + DII + promoter direction, adjusted by crowding
Current data: FII -0.50 pp | DII +0.76 pp | Prom 0.00 pp
Business Momentum
-85
Early weakness
Derived from: Latest quarter sales + profit + OPM change
Current data: Q Sales -2.0% | Q NP -56.1% | Q OPM -4.0 pp
Derived FieldValueHow it is derived
Valuation Gap %-46.3%((Fair Value - CMP) / CMP) × 100
Borrowings / Reserves0.12xLatest borrowings divided by latest reserves
CFO / Net ProfitN/ALatest operating cash flow divided by latest net profit
FII Change-0.50 ppLatest FII% minus previous FII%
DII Change+0.76 ppLatest DII% minus previous DII%
Promoter Change0.00 ppLatest promoter% minus previous promoter%
Shareholder Count Change+6,593Latest shareholder count minus previous count
Quarterly Sales Change-2.0%Latest quarter sales vs previous quarter sales
Quarterly Profit Change-56.1%Latest quarter net profit vs previous quarter net profit
Quarterly OPM Change-4.0 ppLatest quarter OPM minus previous quarter OPM

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 3:45 am

Market Cap 11,934 Cr.
Current Price 312
Intrinsic Value₹167.55
High / Low 1,250/267
Stock P/E39.7
Book Value 99.0
Dividend Yield0.00 %
ROCE14.9 %
ROE12.7 %
Face Value 1.00
PEG Ratio-3.06

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Cohance Lifesciences Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Cohance Lifesciences Ltd 11,934 Cr. 312 1,250/26739.7 99.00.00 %14.9 %12.7 % 1.00
Caplin Point Laboratories Ltd 11,935 Cr. 1,570 2,397/1,50019.4 4160.38 %25.8 %22.7 % 2.00
Jubilant Pharmova Ltd 13,008 Cr. 817 1,250/78428.2 4140.61 %9.54 %9.55 % 1.00
Concord Biotech Ltd 10,671 Cr. 1,020 2,150/99033.6 1741.05 %28.4 %21.4 % 1.00
Alembic Pharmaceuticals Ltd 13,308 Cr. 677 1,108/63520.1 2711.62 %13.0 %11.4 % 2.00
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Cohance Lifesciences Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 354369348231220253488604676840549556545
Expenses 207198181133154180363398439611437435449
Operating Profit 14717216798667312520523722911212195
OPM % 41%47%48%42%30%29%26%34%35%27%20%22%18%
Other Income 131111201417191622-46161
Interest 151022101011101099
Depreciation 12121312131731384454454447
Profit before tax 1461661641056571103174205161638441
Tax % 26%25%26%25%29%25%27%21%25%27%26%21%29%
Net Profit 10812412180475375138153117466629
EPS in Rs 4.234.874.743.131.842.102.965.446.014.731.281.940.96

Last Updated: March 3, 2026, 2:26 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 26, 2026, 1:51 am

MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 3788341,0101,3201,3401,0511,1982,490
Expenses 2064495677387666458221,932
Operating Profit 172385443582574406375558
OPM % 45%46%44%44%43%39%31%22%
Other Income 1666813346625819
Interest 3231291371238
Depreciation 12243239485577190
Profit before tax 158405468668560406344348
Tax % 31%22%23%32%27%26%23%
Net Profit 109317362454411300265259
EPS in Rs 12.4514.2317.8316.1611.8010.528.91
Dividend Payout % 0%20%14%28%37%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)190.83%14.20%25.41%-9.47%-27.01%-11.67%
Change in YoY Net Profit Growth (%)0.00%-176.63%11.22%-34.89%-17.54%15.34%

Cohance Lifesciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 6 years from 2019-2020 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:%
5 Years:8%
3 Years:-3%
TTM:64%
Compounded Profit Growth
10 Years:%
5 Years:-5%
3 Years:-16%
TTM:38%
Stock Price CAGR
10 Years:%
5 Years:22%
3 Years:23%
1 Year:-22%
Return on Equity
10 Years:%
5 Years:21%
3 Years:17%
Last Year:13%

Last Updated: September 5, 2025, 1:41 pm

Balance Sheet

Last Updated: February 1, 2026, 2:00 am

MonthMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 0.0013252525252538
Reserves 5788321,1551,5021,7102,0251,6713,749
Borrowings 83186143977065279451
Other Liabilities 1231421512051601381,0561,330
Total Liabilities 7831,1731,4741,8301,9662,2543,0315,568
Fixed Assets 2713574415346636701,7133,116
CWIP 1111029630165179256357
Investments 7338542598536904337454
Other Assets 3943763956676015017251,641
Total Assets 7831,1731,4741,8301,9662,2543,0315,568

Reserves and Borrowings Chart

Cash Flow

MonthMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 50407383330457358288
Cash from Investing Activity + -65-413-311-136-195-362-253
Cash from Financing Activity + 267-76-156-242-143
Net Cash Flow 111-53720-1838
Free Cash Flow -6304272255171307132
CFO/OP 49%128%111%88%105%115%99%

Free Cash Flow

MonthMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow89.00199.00300.00485.00504.00341.0096.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 142513765304687
Inventory Days 556278243259279268199
Days Payable 19011310097634996
Cash Conversion Cycle 509217180228247265190
Working Capital Days 20564561089910874
ROCE %50%40%41%32%19%15%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 60.00%60.00%60.00%60.00%50.10%50.10%50.10%50.10%50.10%66.41%57.49%57.49%
FIIs 9.47%9.50%10.01%10.14%9.54%9.80%10.70%10.84%11.05%7.23%6.51%6.01%
DIIs 11.43%10.63%14.13%15.94%17.24%17.42%16.95%16.67%16.60%11.40%20.81%21.57%
Government 0.00%0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%
Public 19.10%19.88%15.85%13.93%23.11%22.67%22.26%22.37%22.24%14.95%15.16%14.91%
No. of Shareholders 72,88572,16773,71570,05268,93265,77769,33784,21086,32580,91075,28481,877

Shareholding Pattern Chart

No. of Shareholders

Cohance Lifesciences Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund 6,081,373 2.77 188.494,889,3582026-03-24 01:19:4324.38%
HDFC Balanced Advantage Fund 4,143,548 0.12 128.433,353,0522026-01-26 01:55:1223.58%
HDFC Flexi Cap Fund 4,000,000 0.12 123.98N/AN/AN/A
Invesco India Contra Fund 3,598,511 0.56 111.543,323,9462025-12-15 01:49:318.26%
DSP ELSS Tax Saver Fund 3,285,254 0.59 101.831,910,0662025-12-07 02:39:3072%
ICICI Prudential Value Fund 3,263,091 0.17 101.142,873,3422026-03-24 01:19:4313.56%
DSP Healthcare Fund 2,972,213 3.04 92.122,967,6002026-02-21 14:16:290.16%
DSP Aggressive Hybrid Fund 2,808,197 0.73 87.04N/AN/AN/A
DSP Large & Mid Cap Fund 2,762,648 0.49 85.63N/AN/AN/A
DSP Flexi Cap Fund 2,453,891 0.63 76.061,830,5352025-12-07 02:39:3034.05%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 1.001.001.001.001.00
Basic EPS (Rs.) 10.5211.8016.1617.8314.23
Diluted EPS (Rs.) 10.4511.8016.1617.8314.23
Cash EPS (Rs.) 13.4413.9418.0317.7513.37
Book Value[Excl.RevalReserv]/Share (Rs.) 66.6480.5668.1659.9946.39
Book Value[Incl.RevalReserv]/Share (Rs.) 66.6480.5668.1659.9946.39
Revenue From Operations / Share (Rs.) 47.0441.3052.6551.8639.66
PBDIT / Share (Rs.) 17.0418.3724.0826.3917.86
PBIT / Share (Rs.) 13.9916.2322.2024.8516.62
PBT / Share (Rs.) 13.5115.9421.9924.6116.26
Net Profit / Share (Rs.) 10.4011.8016.1616.2112.12
NP After MI And SOA / Share (Rs.) 10.5211.8016.1617.8314.23
PBDIT Margin (%) 36.2144.4845.7250.8845.03
PBIT Margin (%) 29.7439.2942.1647.9241.90
PBT Margin (%) 28.7138.5841.7647.4540.99
Net Profit Margin (%) 22.1028.5630.6831.2530.56
NP After MI And SOA Margin (%) 22.3628.5630.6834.3735.88
Return on Networth / Equity (%) 15.7814.6423.7029.7130.68
Return on Capital Employeed (%) 13.3619.2431.2739.0733.71
Return On Assets (%) 8.8313.3220.9224.8024.57
Long Term Debt / Equity (X) 0.000.000.000.010.03
Total Debt / Equity (X) 0.040.010.040.060.11
Asset Turnover Ratio (%) 0.450.490.700.800.79
Current Ratio (X) 2.4311.826.375.362.57
Quick Ratio (X) 1.989.654.404.021.66
Inventory Turnover Ratio (X) 6.023.871.441.901.65
Dividend Payout Ratio (NP) (%) 0.000.0049.5122.437.02
Dividend Payout Ratio (CP) (%) 0.000.0044.3620.656.46
Earning Retention Ratio (%) 0.000.0050.4977.5792.98
Cash Earning Retention Ratio (%) 0.000.0055.6479.3593.54
Interest Coverage Ratio (X) 35.1262.77112.74107.8249.73
Interest Coverage Ratio (Post Tax) (X) 22.4441.3076.6667.2334.75
Enterprise Value (Cr.) 29662.0317211.9412039.3615779.1112742.73
EV / Net Operating Revenue (X) 24.7716.378.9811.9512.62
EV / EBITDA (X) 68.3836.8019.6423.4928.02
MarketCap / Net Operating Revenue (X) 24.6616.388.9811.9212.49
Retention Ratios (%) 0.000.0050.4877.5692.97
Price / BV (X) 17.408.406.9310.3010.68
Price / Net Operating Revenue (X) 24.6616.388.9811.9212.49
EarningsYield 0.010.010.030.020.02

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Cohance Lifesciences Ltd. is a Public Limited Listed company incorporated on 06/11/2018 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24299MH2018PLC422236 and registration number is 422236. Currently Company is involved in the business activities of Manufacture of other pharmaceutical and botanical products like hina powder etc.. Company's Total Operating Revenue is Rs. 1093.51 Cr. and Equity Capital is Rs. 25.46 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
Pharmaceuticals215 Atrium, C Wing, 8th Floor, Mumbai Maharashtra 400093Contact not found
Management
NamePosition Held
Mr. Vivek SharmaExecutive Chairman
Dr. V Prasada RajuManaging Director
Mr. Pankaj PatwariNon Executive Director
Ms. Shweta JalanNon Executive Director
Mr. Vinod PadikkalNon Executive Director
Mr. Vinod RaoIndependent Director
Mr. K G AnanthakrishnanIndependent Director
Mr. U B Pravin RaoIndependent Director
Ms. Matangi GowrishankarIndependent Director
Mr. Jai Shankar KrishnanIndependent Director

FAQ

What is the intrinsic value of Cohance Lifesciences Ltd and is it undervalued?

As of 06 April 2026, Cohance Lifesciences Ltd's intrinsic value is ₹167.55, which is 46.30% lower than the current market price of ₹312.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (12.7 %), book value (₹99.0), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Cohance Lifesciences Ltd?

Cohance Lifesciences Ltd is trading at ₹312.00 as of 06 April 2026, with a FY2026-2027 high of ₹1,250 and low of ₹267. The stock is currently near its 52-week low. Market cap stands at ₹11,934 Cr..

How does Cohance Lifesciences Ltd's P/E ratio compare to its industry?

Cohance Lifesciences Ltd has a P/E ratio of 39.7, which is below the industry average of 53.84. This is broadly in line with or below the industry average.

Is Cohance Lifesciences Ltd financially healthy?

Key indicators for Cohance Lifesciences Ltd: ROCE of 14.9 % is moderate. Dividend yield is 0.00 %.

Is Cohance Lifesciences Ltd profitable and how is the profit trend?

Cohance Lifesciences Ltd reported a net profit of ₹265 Cr in Mar 2025 on revenue of ₹1,198 Cr. Compared to ₹454 Cr in Mar 2022, the net profit shows a declining trend.

Does Cohance Lifesciences Ltd pay dividends?

Cohance Lifesciences Ltd has a dividend yield of 0.00 % at the current price of ₹312.00. The company is currently not paying meaningful dividends.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Cohance Lifesciences Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports